Beginning treatment for your lung cancer often brings questions surrounding what side effects will be experienced, according ...

Following the June 2025 FDA approval of Datroway, Dr. Jacob A. Sands explained the significance of the regulatory approval ...

DATROWAY plus pembrolizumab with or without platinum-based chemotherapy show consistent tumor responses as first-line treatment of advanced NSCLC Final results from the TROPION-Lung02 phase 1b ...

DATROWAY is approved in more than 30 countries worldwide for the treatment of adult patients with unresectable or metastatic HR-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer ...

DATROWAY (6mg/kg) is approved in the US and Japan for the treatment of adult patients with unresectable or metastatic HR-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who ...

DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who ...

AstraZeneca AZN announced that the FDA has expanded the label of its cancer drug Datroway for a second indication — non-small cell lung cancer (NSCLC). The drug has been developed in partnership ...

DATROWAY ® has been approved in the US for the treatment of adult patients with locally advanced or metastatic EGFR- mutated non-small cell lung cancer who have received prior EGFR- directed ...

DATROWAY® Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer TROPION-Lung02 and TROPION-Lung04 phase 1b ...

TOKYO & MUNICH, April 08, 2025--DATROWAY® (datopotamab deruxtecan) has been approved in the European Union (EU) for the treatment of adult patients with unresectable or metastatic hormone ...